Fig. 5: PRMT3 is required for the GBM tumor formation and progression in vivo.

A Representative images (left) and weights (right) of tumors formed in the flanks of nude mice injected with GBM cells that were transfected with control or lenti-shPRMT3. Data are presented as means ± SEM; n = 5 animals/group. **p < 0.01; ***p < 0.001; two-tailed unpaired Student t-test. B Tumors stained for cleaved-caspase3 from mice injected with U87 cells that were transfected with control or lenti-shPRMT3 (left) and quantifications (right) of CC3 positive cells. Data are presented as means ± SEM; n = 4 independent experiments; **p < 0.01; ***p < 0.001; two-tailed unpaired Student t-test. C Representative bioluminescent images of mice transplanted with Ctrl or PRMT3-KD GSC20 cells. Bar graph: average photon flux at each time point. D Kaplan-Meier survival curve of mice. Log-rank test. E Representative images of tumors stained with H&E. F Representative images of tumors stained with BrdU (left) and quantifications (right) of BrdU positive cells. Data are presented as means ± SEM; n = 3 independent experiments; **p < 0.01; ***p < 0.001; two-tailed unpaired Student t-test. G Tumors stained for cleaved-caspase3 from mouse xenografts with GSC20 cells that were transduced with control or lenti-shPRMT3 (left) and quantifications (right) of CC3 positive cells. Data are presented as means ± SEM; n = 5 animals/group. **p < 0.01; ***p < 0.001; two-tailed unpaired Student t-test.